Posts by Mourabit Halima

Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy, with FLT3 mutations among the most common molecular abnormalities, significantly impacting patient prognosis. As our understanding of AML pathogenesis deepens, novel targeted therapies, including FLT3 inhibitors, have emerged, offering new hope for patients with FLT3-mutated AML. From January 17 to 19, 2025, the "CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting & 2025 CSCO Hematologic Oncology Conference" was held in Haikou, China. During the event, Hematology Frontier had the privilege of interviewing Dr. Hui Wei from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences. He shared insights into the prevalence of FLT3 mutations in AML, recent advancements in targeted therapy, and future optimization strategies.

Presented at ASH 2024, this study explores the critical role of Platelet Factor 4 (PF4) in regulating hematopoietic stem cell (HSC) aging. HSCs are essential for lifelong blood cell production,…

As the new year begins, the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (2025 CASH) took place from January 3 to 5 in Tianjin. With the theme of “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being,” the event brought together leading experts and scholars in hematology to discuss the latest advances and future directions in the field. The Haihe Laboratory of Cell Ecosystem, a high-level research platform established in Tianjin, plays a pivotal role in advancing hematology.

Let's unite to raise awareness and support those affected by lymphoma! Early detection, research, and innovative treatments are key to fighting this disease. Together, we can make a difference and…

Editor's Note：Acute leukemia is a group of malignant hematological diseases that pose a serious threat to human health, making its treatment a major focus of medical research. At the 2024…

From January 3–5, 2025, the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (CASH) was held in Tianjin under the theme “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” The event gathered leading experts from China and abroad to discuss the latest advancements and future trends in hematology. Professor Jun Shi, Deputy Director of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences , followed up on his remarkable presentation at last year’s CASH conference with an update on lentiviral vector gene therapy for thalassemia.In this exclusive feature, Hematology Frontier invited Professor Shi to share the promising clinical results achieved by his team and outline their future research plans.